Cargando…

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

BACKGROUND: We evaluated the therapeutic efficacy of GC1118, a novel anti‐epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification. METHODS: This study was a multicenter, open‐label, single‐arm phase II trial. Recurrent GBM patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Seung Won, Jung, Hyun Ae, Cho, Hee‐Jin, Kim, Tae Min, Park, Chul‐Kee, Nam, Do‐Hyun, Lee, Se‐Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469652/ https://www.ncbi.nlm.nih.gov/pubmed/37537946 http://dx.doi.org/10.1002/cam4.6213

Ejemplares similares

Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts
por: Lee, Hye Won, et al.
Publicado: (2019)

A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors
por: Chung, Tae Kyu, et al.
Publicado: (2021)

EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status
por: Dhawan, Andrew, et al.
Publicado: (2023)

EGFR Amplification and Glioblastoma Stem-Like Cells
por: Liffers, Katrin, et al.
Publicado: (2015)

Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma
por: Hu, Leland S., et al.
Publicado: (2021)

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco
por: Senhaji, Nadia, et al.
Publicado: (2017)

Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients
por: Bieńkowski, Michał, et al.
Publicado: (2013)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis
por: Talasila, Krishna M., et al.
Publicado: (2013)

The miR-183/96/182 cluster is upregulated in glioblastoma carrying EGFR amplification
por: Schneider, Björn, et al.
Publicado: (2022)

The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
por: Kaye, Brandon, et al.
Publicado: (2023)

Mechanisms of EGFR Resistance in Glioblastoma
por: Pan, Peter C., et al.
Publicado: (2020)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

Correlation between EGFR Amplification and the Expression of MicroRNA-200c in Primary Glioblastoma Multiforme
por: Serna, Eva, et al.
Publicado: (2014)

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma
por: Muñoz-Hidalgo, Lisandra, et al.
Publicado: (2019)

Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma
por: Walentynowicz, Kacper A., et al.
Publicado: (2023)

Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report
por: Zhou, Ke, et al.
Publicado: (2017)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Targeting immunoliposomes to EGFR-positive glioblastoma
por: Kasenda, B., et al.
Publicado: (2022)

A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
por: Oh, Do‐Youn, et al.
Publicado: (2019)

Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme
por: William, Doreen, et al.
Publicado: (2017)

Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
por: Fontanilles, Maxime, et al.
Publicado: (2020)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification
por: Dekanić, Andrea, et al.
Publicado: (2011)

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
por: Lassman, Andrew B, et al.
Publicado: (2019)

Defining EGFR amplification status for clinical trial inclusion
por: French, Pim J, et al.
Publicado: (2019)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
por: Kim, Chi Hong, et al.
Publicado: (2015)

EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma
por: Ravanpay, Ali C., et al.
Publicado: (2019)

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
por: Kim, Hye Ryeon, et al.
Publicado: (2023)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8re1574apciffm32cid8431fvo